Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of MSB2311 in advanced solid tumors
NCT04272944Phase 1Completed
- Sponsor
- Transcenta
- Start
- Aug 2018
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MSB2311 in solid tumor (2 arms), sponsored by Transcenta. Primary endpoints: Safety and tolerability of MSB2311 and Maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D). Started Aug 2018; status: completed.
02
Drugs
MSB2311
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04272944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04272944.